About
OncoC4 develops therapeutics targeting innate and adaptive immune checkpoints such as CTLA-4, PD-1/VEGF, Siglec, and CD24 to treat hard-to-treat cancers and Alzheimer's disease using modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.
Explore OncoC4's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.